Dostarlimab + chemo in pA/rEC: PFS & OS by molecular classification in ENGOT-EN6-NSGO/GOG-3031/RUBY скачать в хорошем качестве

Dostarlimab + chemo in pA/rEC: PFS & OS by molecular classification in ENGOT-EN6-NSGO/GOG-3031/RUBY

Mansoor Raza Mizra, MD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the Phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial (NCT03981796), which examined the efficacy of dostarlimab (D) in combination with carboplatin-paclitaxel compared to carboplatin-paclitaxel alone for patients with primary advanced or recurrent endometrial cancer (pA/rEC). The trial showed that dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival (PFS) in the mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) and overall patient populations. Additionally, a favorable trend in overall-survival (OS) was observed. The study identified four molecular subgroups, including POLε mutation (mut), dMMR/MSI-H, TP53 abnormal, and no specific molecular profile (NSMP). The combination therapy demonstrated enhanced PFS and OS in the dMMR/MSI-H, TP53mut, and NSMP subgroups. POLεmut patients had the best prognosis. Further research is needed to validate these findings. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.